Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.55 |
| ▸ | AR | P10275 | 4/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | BTK | Q06187 | 2/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.44 |
| ▸ | PLK4 | O00444 | 1/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 1/20 | 0.41 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23268079 | 0.91 | CRBN (0.69) | CRBNARCDK9BTKIRAK1 | |
| SCHEMBL27099492 | 0.90 | CRBN (0.58) | CRBNARCDK9BTKDDB1 | |
| SCHEMBL21771314 | 0.89 | CRBN (0.65) | CRBNDDB1 | |
| SCHEMBL24819369 | 0.87 | CRBN (0.69) | CRBNARCDK9BTKPLK4 | |
| SCHEMBL27099498 | 0.87 | CRBN (0.59) | CRBNBRD9DDB1EGFR | |
| SCHEMBL27099506 | 0.86 | CRBN (0.61) | CRBNARALKBRD9DDB1 | |
| SCHEMBL23875287 | 0.85 | CRBN (0.49) | CRBNARCDK9BTKIRAK1 | |
| SCHEMBL27099504 | 0.84 | CRBN (0.61) | CRBNARDDB1 | |
| SCHEMBL25691426 | 0.83 | CRBN (0.47) | CRBNARCDK9BTKIRAK1 | |
| SCHEMBL25691418 | 0.83 | CRBN (0.47) | CRBNARCDK9BTKIRAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | ARVINAS OPERATIONS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912699-B2 | Tau-protein targeting compounds and associated | MAPT, VHL, CRBN | CRBN 3/4885AR 3157/4885CDK9 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.